Regeneron Pharmaceuticals, Inc. (REGN)
Data as of September 4, 2026 · Biotechnology
Stockbruh grade: Mixed 3/5 metrics rated Sunny
What does Regeneron Pharmaceuticals, Inc. do?
Regeneron Pharmaceuticals is the cool kid in the medical world, discovering and developing treatments for all sorts of diseases. With headquarters in Tarrytown, New York, they've got their eyes on creating innovative products like EYLEA for eye problems and Dupixent for skin issues like atopic dermatitis. They're even taking on COVID-19 with their REGEN-COV treatment. Regeneron is all about making your health a top priority, so you can live your best life.
Key Numbers
| Metric | Rating | What it means |
|---|
| Returns (5Y) | ⛅ Moderate | 5-year price performance |
| Profitability | ☀️ Strong | Net margin & return on equity |
| Growth | ⛅ Moderate | Revenue & earnings trend |
| Earnings | ☀️ Strong | EPS vs analyst expectations |
| Cash & Debt | ☀️ Strong | Balance sheet strength |
| Price | $842.21 | Market Cap | — |
| Exchange | NASDAQ Global Select | | |
Plain-English Analysis
What's it worth?
Performance has been moderate. Sign up free to see Stockbruh's full valuation analysis including price ratios and plain-English commentary.
How the business works
Regeneron Pharmaceuticals is the cool kid in the medical world, discovering and developing treatments for all sorts of diseases. With headquarters in Tarrytown, New York, they've got their eyes on creating innovative products like EYLEA for eye problems and Dupixent for skin issues like atopic dermatitis. Sign up free for competitor and revenue breakdown ↗
Are they building the future?
Growth is mixed — some positive signals, but not consistent. Sign up free for Stockbruh's full growth breakdown.
What's ahead?
Recent earnings have been strong, meeting or beating analyst expectations. Sign up free for earnings history, EPS trends, and what analysts are forecasting next.